Please find below information about clinical trials that the Colorado Posterior Atrophy is involved with, past and present.
The NIH and the Alzheimer’s Association is sponsoring an important study that will shape the way we understand, and eventually treat, people who develop symptoms of Alzheimer’s disease between 40 and 64 years of age. Currently, PCA syndrome is underrepresented. I urge you to consider contacting the study group to see if you can participate. Read more about it HERE
Study Team and how to contact them: Telephone: 317-963-7436 Email: iuLEADS@iupui.edu
Eligibility for inclusion is listed below. It is okay if you do not understand these terms because the study team will walk you through eligibility.
1. Meets NIA-AA criteria for mild cognitive impairment due to Alzheimer’s disease (AD) or probable AD dementia
2. Have a global CDR score ≤ 1.0
3. Have capacity to provide informed consent (IC) or has a legal authorized representative or guardian who provides IC
4. Age between 40-64 years (inclusive) at the time of consent
5. Must have a study partner (informant) who spends a minimum average of at least 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participants’ daily activities and can provide information about the participant’s cognitive and functional performance. If the participant does not have a study partner who spends 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI
6. Willing and able to complete longitudinal study procedures aside from LP which is an optional procedure
7. Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan
In the Department of Neurology at University of Colorado School of Medicine, we have active research studies that are currently enrolling people with PCA. Each of these studies are observational studies. This means that they are not treatment studies. The studies are aimed at learning more about PCA and the diseases that cause PCA. The knowledge gained from both studies will be important for understand the best way to design treatment trials in the future and to advance our understanding of diseases that cause PCA.
The first of these ongoing studies is designed for PCA and is called the Colorado BioPCA Registry. Inclusion in the study is possible if a person meets criteria for PCA and is a patient of Dr. Pelak at the University of Colorado Health clinics. The study involves agreeing to allow Dr. Pelak and her research term to utilize information and test results collected during routine visits for health care and that are available in the electronic medical record. Enrollment in the study does not involve any study visits. All the information is collected directly form the electronic medical record. If you are interested in the study and are a patient of Dr. Pelak, please let Dr. Pelak know or email email@example.com to express your interest.
The second study is called theBio-AD Study, and this study is focused on collecting markers of disease (blood and MRI scans, for instance) from individuals who have either been diagnosed with Alzheimer’s disease, Down Syndrome, or Mild Cognitive Impairment, as well as healthy older adults. This study hopes that by looking at the various biomarkers in the blood, investigators can better understand how they influence the clinical features of aging and Alzheimer’s disease. It is a longitudinal study, which means participants are asked to come in once a year for four years. For more information about the study, please email: firstname.lastname@example.org.
Because of your generous donations, we were able to hire two interns for the summer of 2019. In July 2019 we launched our Summer Internship Program for PCA Research and we received a large number of spectacular applications. We awarded the internship to two CU medical students, Stephanie Serva and Vishal Krishnan. They attended a support group meeting, visited with patients outside of clinics, and collected and analyzed data for the Colorado PCA BioBank and Registry study. They submitted an abstract to the International Neuropsychological Society 2020 Annual Meeting titled “Patient Characteristics from the Colorado Posterior Cortical Atrophy BioRegistry” and their abstract was accepted. They presented their findings in early 2020.
2019 Summer PCA Research Interns, Stephanie Serva and Vishal Krishnan, presented their work on PCA at the International Neuropsychological Society Meeting in February 2020 with great success.
Stephanie Serva, in 2019, was a rising second-year medical student at the University of Colorado. She was born in Connecticut where she grew up with her parents, younger brother, and lots of dogs! She received her Bachelor’s
degree in Biomedical Science from Colorado State University in 2016 and went on to complete a Master’s degree in Medical Science at Boston University in 2018. In her free time, Stephanie enjoys hiking, yoga, and exploring new restaurants.
Vishal Krishnan, in 2019, was a first-year medical student who aspires to be a physician who makes an impact both in the clinic and in his community. He went to college at Washington University in St. Louis and has a Bachelor of Arts
degree in Neuroscience. He has a keen interest in medical research, partaking in neurological research related to Alzheimer’s disease as an undergraduate. He is of Indian Ancestry, was born in Houston, raised in Singapore, and has been based
in Colorado for the past 14 years.
Opens in a new windowOpens document in a new window